Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
354 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (3)

Medical Condition

  • Show all (90)
  • Autoimmune Disorders (1)
  • Blood Disorders (4)
  • Bone & Muscle (1)
  • Cancer (23)
    • Breast Cancer (1)
    • (-) Gynecologic Cancer (2)
    • Head and Neck Cancer (1)
    • Leukemia (3)
    • Liver Cancer (1)
    • Lung Cancer (2)
    • Lymphoma (1)
    • Multiple Myeloma (2)
    • Pancreatic Cancer (1)
    • (-) Prostate Cancer (1)
    • Solid Tumors (2)
    • Uveal Melanoma (2)
  • COVID-19 (Coronavirus) (4)
  • Diabetes (2)
  • Endocrine & Metabolic Disease (3)
  • Healthy Volunteers (10)
  • Heart Disease (17)
  • Kidney Disease (1)
  • Liver Disease (1)
  • Lung Disease (2)
  • Neurological Disorders (3)
  • Nutrition (1)
  • Obesity (2)
  • Obstetrics & Gynecology (3)
  • Pediatrics (7)
  • Surgery (2)
  • Transplant (3)
Displaying 1 - 3 of 3

Study of JNJ-78278343 in Patients with Advanced Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
You are being invited to take part in a research study that includes studying JNJ-78278343 in subjects with prostate cancer. This is an investigational drug which means that this is a new approach for the treatment of people who have prostate cancer. The main purpose of this study is to find a safe dose of JNJ-78278343 that can be used in the treatment of…
Read More

Study of SL-172154 in Combination with PLD or MIRV in Patients with Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing…
Read More

Study of Upifitamab Rilsodotin (XMT-1536) in Patients with Recurrent Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
XMT-1536 (upifitamab rilsodotin) is a targeted therapy, which means that it is directed specifically at a tumor. It is a type of antibody-drug conjugate; this means it has 2 parts that are joined together into one drug. The first part is an antibody that binds to NaPi2b (sodium-dependent phosphate transporter), a protein on the surface of the cells of your…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science